Literature DB >> 28534528

Combining drugs and extending treatment - a PFS end point is not sufficient.

Bishal Gyawali1, Vinay Prasad2,3,4.   

Abstract

Mesh：

Year:  2017        PMID： 28534528     DOI： 10.1038/nrclinonc.2017.72

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Progression-free survival: meaningful or simply measurable?

Authors:  Christopher M Booth; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

Review 2.  The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.

Authors:  Vinay Prasad; Chul Kim; Mauricio Burotto; Andrae Vandross
Journal:  JAMA Intern Med       Date:  2015-08       Impact factor: 21.873

3.  Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.

Authors:  Sham Mailankody; Vinay Prasad
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

4.  Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse.

Authors: 
Journal:  Clin Adv Hematol Oncol       Date:  2016-02

5.  Routine Cancer Antigen 125 Surveillance-The Fatal Attraction of Testing.

Authors:  James S Goodwin
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

6.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

7.  Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study.

Authors:  N H Hanna; A B Sandier; P J Loehrer; R Ansari; S H Jung; K Lane; L H Einhorn
Journal:  Ann Oncol       Date:  2002-01       Impact factor: 32.976

8.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski
Journal:  Lancet       Date:  2015-03-19       Impact factor: 79.321
  8 in total
  3 in total

Review 1.  Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper.

Authors:  Esther Bastiaannet; Nicolò Battisti; Kah Poh Loh; Nienke de Glas; Enrique Soto-Perez-de-Celis; Capucine Baldini; Ellen Kapiteijn; Stuart Lichtman
Journal:  J Geriatr Oncol       Date:  2018-07-17       Impact factor: 3.599

2.  Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study.

Authors:  Charlotte Ouimet; Gauthier Bouche; Jonathan Kimmelman
Journal:  PLoS One       Date:  2022-09-12       Impact factor: 3.752

3.  Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review.

Authors:  John Sharp; Ali Raza Khaki; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2021-09-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.